Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies

Paolo Airo', Angela Ceribelli, Ilaria Cavazzana, Mara Taraborelli, Stefania Zingarelli, Franco Franceschini

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objective. To evaluate the frequency of malignancies in Italian patients with systemic sclerosis (SSc) and anti-RNA polymerase III (RNAP III), antitopoisomerase I (topo I), or anticentromere antibodies (ACA); and to characterize the temporal relationship between the 2 diseases, in order to confirm data suggesting a close temporal relationship between the onset of SSc and malignancy in American patients with anti-RNAP III antibodies. Methods. From a cohort of 466 consecutive SSc patients, 360 Italians with isolated positivity for anti-RNAP III (n = 16), anti-topo I (n = 101), or ACA (n = 243) were identified. Malignancy cases were divided according to their relationship with SSc onset into 3 categories: preceding, synchronous with, or metachronous to the onset of SSc (diagnosed more than 6 months before; 6 months before to 12 months after; and more than 12 months after onset of SSc, respectively). Results. Malignancies were more frequent in the anti-RNAP III group (7/16 patients), than in the anti-topo I (11/101) and ACA groups (21/243) (p <0.001). This difference was accounted for by the number of patients with cancer synchronous to the onset of SSc (3/16 in the anti-RNAP III group vs 0/101 in the anti-topo I and 1/243 in the ACA group; p <0.001), whereas neither the number of malignancies preceding nor those metachronous to the onset of SSc was significantly different between the groups. Conclusion. In a cohort of Italian patients with SSc we observed a significant association between malignancies synchronous to SSc onset and positivity for anti-RNAP III antibodies, similar to that described in American patients with SSc. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)1329-1334
Number of pages6
JournalJournal of Rheumatology
Volume38
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

RNA Polymerase III
Systemic Scleroderma
Antibodies
Neoplasms
Rheumatology

Keywords

  • Anti-RNA polymerase III antibodies
  • Anticentromere antibodies
  • Antitopoisomerase I antibodies
  • Malignancy
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. / Airo', Paolo; Ceribelli, Angela; Cavazzana, Ilaria; Taraborelli, Mara; Zingarelli, Stefania; Franceschini, Franco.

In: Journal of Rheumatology, Vol. 38, No. 7, 07.2011, p. 1329-1334.

Research output: Contribution to journalArticle

Airo', Paolo ; Ceribelli, Angela ; Cavazzana, Ilaria ; Taraborelli, Mara ; Zingarelli, Stefania ; Franceschini, Franco. / Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. In: Journal of Rheumatology. 2011 ; Vol. 38, No. 7. pp. 1329-1334.
@article{3c13ea07550a4019b43a21f290ef6c6d,
title = "Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies",
abstract = "Objective. To evaluate the frequency of malignancies in Italian patients with systemic sclerosis (SSc) and anti-RNA polymerase III (RNAP III), antitopoisomerase I (topo I), or anticentromere antibodies (ACA); and to characterize the temporal relationship between the 2 diseases, in order to confirm data suggesting a close temporal relationship between the onset of SSc and malignancy in American patients with anti-RNAP III antibodies. Methods. From a cohort of 466 consecutive SSc patients, 360 Italians with isolated positivity for anti-RNAP III (n = 16), anti-topo I (n = 101), or ACA (n = 243) were identified. Malignancy cases were divided according to their relationship with SSc onset into 3 categories: preceding, synchronous with, or metachronous to the onset of SSc (diagnosed more than 6 months before; 6 months before to 12 months after; and more than 12 months after onset of SSc, respectively). Results. Malignancies were more frequent in the anti-RNAP III group (7/16 patients), than in the anti-topo I (11/101) and ACA groups (21/243) (p <0.001). This difference was accounted for by the number of patients with cancer synchronous to the onset of SSc (3/16 in the anti-RNAP III group vs 0/101 in the anti-topo I and 1/243 in the ACA group; p <0.001), whereas neither the number of malignancies preceding nor those metachronous to the onset of SSc was significantly different between the groups. Conclusion. In a cohort of Italian patients with SSc we observed a significant association between malignancies synchronous to SSc onset and positivity for anti-RNAP III antibodies, similar to that described in American patients with SSc. The Journal of Rheumatology",
keywords = "Anti-RNA polymerase III antibodies, Anticentromere antibodies, Antitopoisomerase I antibodies, Malignancy, Systemic sclerosis",
author = "Paolo Airo' and Angela Ceribelli and Ilaria Cavazzana and Mara Taraborelli and Stefania Zingarelli and Franco Franceschini",
year = "2011",
month = "7",
doi = "10.3899/jrheum.101144",
language = "English",
volume = "38",
pages = "1329--1334",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "7",

}

TY - JOUR

T1 - Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies

AU - Airo', Paolo

AU - Ceribelli, Angela

AU - Cavazzana, Ilaria

AU - Taraborelli, Mara

AU - Zingarelli, Stefania

AU - Franceschini, Franco

PY - 2011/7

Y1 - 2011/7

N2 - Objective. To evaluate the frequency of malignancies in Italian patients with systemic sclerosis (SSc) and anti-RNA polymerase III (RNAP III), antitopoisomerase I (topo I), or anticentromere antibodies (ACA); and to characterize the temporal relationship between the 2 diseases, in order to confirm data suggesting a close temporal relationship between the onset of SSc and malignancy in American patients with anti-RNAP III antibodies. Methods. From a cohort of 466 consecutive SSc patients, 360 Italians with isolated positivity for anti-RNAP III (n = 16), anti-topo I (n = 101), or ACA (n = 243) were identified. Malignancy cases were divided according to their relationship with SSc onset into 3 categories: preceding, synchronous with, or metachronous to the onset of SSc (diagnosed more than 6 months before; 6 months before to 12 months after; and more than 12 months after onset of SSc, respectively). Results. Malignancies were more frequent in the anti-RNAP III group (7/16 patients), than in the anti-topo I (11/101) and ACA groups (21/243) (p <0.001). This difference was accounted for by the number of patients with cancer synchronous to the onset of SSc (3/16 in the anti-RNAP III group vs 0/101 in the anti-topo I and 1/243 in the ACA group; p <0.001), whereas neither the number of malignancies preceding nor those metachronous to the onset of SSc was significantly different between the groups. Conclusion. In a cohort of Italian patients with SSc we observed a significant association between malignancies synchronous to SSc onset and positivity for anti-RNAP III antibodies, similar to that described in American patients with SSc. The Journal of Rheumatology

AB - Objective. To evaluate the frequency of malignancies in Italian patients with systemic sclerosis (SSc) and anti-RNA polymerase III (RNAP III), antitopoisomerase I (topo I), or anticentromere antibodies (ACA); and to characterize the temporal relationship between the 2 diseases, in order to confirm data suggesting a close temporal relationship between the onset of SSc and malignancy in American patients with anti-RNAP III antibodies. Methods. From a cohort of 466 consecutive SSc patients, 360 Italians with isolated positivity for anti-RNAP III (n = 16), anti-topo I (n = 101), or ACA (n = 243) were identified. Malignancy cases were divided according to their relationship with SSc onset into 3 categories: preceding, synchronous with, or metachronous to the onset of SSc (diagnosed more than 6 months before; 6 months before to 12 months after; and more than 12 months after onset of SSc, respectively). Results. Malignancies were more frequent in the anti-RNAP III group (7/16 patients), than in the anti-topo I (11/101) and ACA groups (21/243) (p <0.001). This difference was accounted for by the number of patients with cancer synchronous to the onset of SSc (3/16 in the anti-RNAP III group vs 0/101 in the anti-topo I and 1/243 in the ACA group; p <0.001), whereas neither the number of malignancies preceding nor those metachronous to the onset of SSc was significantly different between the groups. Conclusion. In a cohort of Italian patients with SSc we observed a significant association between malignancies synchronous to SSc onset and positivity for anti-RNAP III antibodies, similar to that described in American patients with SSc. The Journal of Rheumatology

KW - Anti-RNA polymerase III antibodies

KW - Anticentromere antibodies

KW - Antitopoisomerase I antibodies

KW - Malignancy

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=79959952892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959952892&partnerID=8YFLogxK

U2 - 10.3899/jrheum.101144

DO - 10.3899/jrheum.101144

M3 - Article

VL - 38

SP - 1329

EP - 1334

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 7

ER -